Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/88773
Title: | Safety of vitamin K antagonist treatment for splanchnic vein thrombosis : a multicenter cohort study |
Authors: | Riva, Nicoletta Ageno, Walter Poli, Daniela Testa, Sophie Rupoli, Serena Santoro, Rita Lerede, Teresa Piana, Antonietta Carpenedo, Monica Nicolini, Alberto Ferrini, Piera Maria Tosetto, Alberto |
Keywords: | Anticoagulants (Medicine) Anticoagulants (Medicine) -- Administration Vitamin K Thrombosis |
Issue Date: | 2015 |
Publisher: | International Society on Thrombosis and Haemostasis |
Citation: | Riva, N., Ageno, W., Poli, D., Testa, S., Rupoli, S., Santoro, R., ... & Molinatti, M. (2015). Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study. Journal of Thrombosis and Haemostasis, 13(6), 1019-1027. |
Abstract: | Background: The treatment of splanchnic vein thrombosis (SVT) is challenging, due to the increased risk of bleeding and potentially life-threatening complications. Current recommendations are based on evidence from the treatment of venous thrombosis in usual sites, but small observational studies in SVT population suggest that the bleeding risk may offset the benefit of anticoagulant treatment in this setting. The aim of this study was to evaluate the safety of vitamin K antagonists (VKAs) in SVT patients. Methods: We retrospectively included SVT patients treated with VKAs followed by 37 Italian anticoagulation clinics, until June 2013. The primary outcome was the incidence of major bleeding (MB), according to the ISTH definition, during VKA treatment. Vascular events, including both arterial and venous thrombosis, and mortality were also documented. Results: Three hundred and seventy-five patients were included (median age 53 years; 54.7% males). During a median VKA treatment duration of 1.98 years, 15 MB events occurred, corresponding to an incidence rate of 1.24 (95% confidence interval [CI], 0.75–2.06) per 100 patient-years. Gastrointestinal bleeding represented 40% of all MB events. At multivariate analysis, the presence of esophageal varices emerged as independent predictor of MB (hazard ratio 5.4; 95% CI, 1.4–21.1). The incidence rate of vascular events on treatment was 1.37 (95% CI, 0.84–2.23) per 100 patient-years and the mortality rate was 0.83 (95% CI, 0.44–1.54) per 100 patient-years. Conclusions: Selected SVT patients followed by anticoagulation clinics for the management of VKA treatment show a low rate of major bleeding and vascular events |
URI: | https://www.um.edu.mt/library/oar/handle/123456789/88773 |
Appears in Collections: | Scholarly Works - FacM&SPat |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Safety of vitamin K antagonist treatment for splanchnic vein thrombosis.pdf Restricted Access | 192.79 kB | Adobe PDF | View/Open Request a copy |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.